Cited by 964Tuberculosis Research and EpidemiologyMycobacterium research and diagnosisBacterial Identification and Susceptibility Testing

Rapid, Low-Technology MIC Determination with Clinical Mycobacterium tuberculosis Isolates by Using the Microplate Alamar Blue Assay

Open access
Franzblau, Scott G., Witzig, Richard S., McLaughlin, James C., Torres, Patricia, Madico, Guillermo, Hernandez, Antonio, Degnan, Michelle T., Cook, Mary B. +3 more·1998·Journal of Clinical Microbiology

Abstract

A colorimetric, microplate-based Alamar Blue assay (MABA) method was used to determine the MICs of isoniazid (INH), rifampin, streptomycin (SM), and ethambutol (EMB) for 34 Peruvian Mycobacterium tuberculosis isolates (including both pansensitive and multidrug-resistant strains) and the H 37 Rv strain by using bacterial suspensions prepared directly from solid media. Results for all isolates were available within 8 days. Discordant results were observed on initial tests for 3 of 16 INH-susceptible isolates, 5 of 31 EMB-susceptible isolates, and 2 of 4 SM-resistant isolates (by the BACTEC 460 system). The overall agreements between the MICs obtained by MABA and the results obtained with the BACTEC 460 system were 87.9% for initial results and 93.6% after retesting 12 of 17 samples with discrepant results. Interpretation of MABA endpoints improved with technical experience. The MABA is a simple, rapid, low-cost, appropriate technology which does not require expensive instrumentation and which makes use of a nontoxic, temperature-stable reagent.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/jcm.36.2.362-366.1998

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Preliminary studies of DST of MDR TB isolates using MTT, Alamar blue, or resazurin showed a good correlation with the conventional proportion method.

    “Preliminary studies of DST of MDR TB isolates using MTT, Alamar blue, or resazurin showed a good correlation with the conventional PM (1, 13, 19, 20, 31, 37, 49).”

    From Resazurin Microtiter Assay Plate Testing of <i>Mycobacterium tuberculosis</i> Susceptibilities to Second-Line Drugs: Rapid, Simple, and Inexpensive Method (2003) · cites this paper as [20]

    The paper’s introduction reports good correlation between Alamar Blue testing and the proportion technique in an earlier study of clinical isolates. This paper’s own study included multidrug-resistant isolates, but compared Alamar Blue results with BACTEC 460, not the conventional proportion method. Its Discussion describes MTT results as preliminary and similar to Alamar Blue results; it does not establish proportion-method correlation for MTT or resazurin as separate assays. Page numbers are unavailable in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • A rapid and inexpensive colorimetric method based on Alamar blue and MTT has been successfully used for determining MICs of first-line drugs in DST of M. tuberculosis.

    “A rapid and inexpensive colorimetric method based on the oxidation-reduction indicators Alamar blue and MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium] have been successfully used for determining MICs of first-line drugs in DST of Mycobacterium tuberculosis (1, 9, 20, 31, 38, 49).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 4

  1. [1]1. Cohn, D. L., F. Bustreo, and M. C. Raviglione. 1997. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project. Clin. Infect. Dis. 24 (Suppl. 1) : S121-S130.
  2. [4]4. Hacek, D. 1992. Modified proportion agar dilution test for slowly growing mycobacteria, p. 5.13.1-5.13.15. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook, vol. 1. American Society for Microbiology, Washington, D.C.
  3. [7]7. Inderlied, C. B., and M. Salfinger. 1995. Antimicrobial agents and susceptibility tests: mycobacteria, p. 1385-1404. In P. R. Murray, E. J. Barron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. ASM Press, Washington, D.C.
  4. [6]6. Hindler, J., L. Hochstein, and A. Howell. 1992. Preparation of routine media and reagents used in antimicrobial susceptibility testing. Part 1. McFarland standards, p. 5.19.1-5.19.6. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook, vol. 1. American Society for Microbiology, Washington, D.C.

Cited by

Sorted by citations

Authors
Franzblau, S. G., Witzig, R. S., McLaughlin, J. C., Torres, P., Madico, G., Hernandez, A., Degnan, M. T., Cook, M. B., Quenzer, V. K., Ferguson, R. M., & Gilman, R. H.
Affiliations
  • <!--label omitted: 1-->GWL Hansen’s Disease Center, Baton Rouge, Louisiana1;
  • Johns Hopkins University (US)
  • University of New Mexico (US)
  • Universidad Peruana Cayetano Heredia (PE)
  • <!--label omitted: 3-->University of New Mexico Health Science Center3 and
  • New Mexico Department of Health (US)
Venue
Journal of Clinical Microbiology
Published
1998-02
Volume
36
Issue
2
Pages
362-366
ISSN
  • 0095-1137 (ISSN-L)
  • 1098-660X
OpenAlex
W2160787060
Cited by
964
References
0
Citations by year
2026: 29 · 2025: 35 · 2024: 42 · 2023: 40 · 2022: 41 · 2021: 42 · 2020: 29 · 2019: 34 · 2018: 44 · 2017: 50 · 2016: 44 · 2015: 59 · 2014: 64 · 2013: 55 · 2012: 45
FWCI
5.29
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Microbiology (publishedVersion)
  • PubMed Central (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Allergy and Infectious Diseases (N01 AI050016, Y1-AI-50016)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Bacterial Identification and Susceptibility Testing
Keywords
Mycobacterium tuberculosis, antimicrobial susceptibility testing, Alamar Blue assay, microplate assay, isoniazid, rifampicin, streptomycin, ethambutol, multidrug-resistant tuberculosis, Peru
MeSH terms
Antibiotics, Antitubercular, Antitubercular Agents, Bacteriological Techniques, Culture Media, Drug Resistance, Microbial, Coloring Agents, Ethambutol, Humans, Isoniazid, Microbial Sensitivity Tests, Mycobacterium tuberculosis, Oxazines, Peru, Rifampin, Sensitivity and Specificity, Streptomycin, Tuberculosis, Xanthenes, Drug Resistance, Multiple

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review